DOI: https://dx.doi.org/10.18203/issn.2455-4510.IntJResOrthop20214974
Published: 2021-12-24

Oncogenic osteomalacia secondary to hemangiopericytoma: a case report

Aamir Matin, Sushant Sopan Tuse

Abstract


We are going to present a case of hypo-phosphatemic rickets secondary to phosphaturic mesenchymal tumour who came with complaints of proximal muscle weakness which limited his effort tolerance and activities of daily life like standing from squatting position and rib pain. His FGF-23 levels were very high above normal levels and PET CT revealed a well-defined enhancing lesion abutting femoral neurovascular bundle. After consultation with endocrinologist, we have d done complete excision of the mass. Post-surgery all symptoms were relieved, proximal muscle strength improved gradually and serum levels of phosphorus, ALP and FGF-23 came back to normal.


Keywords


Fibroblast growth factor-23, Phosphaturic mesenchymal tumour, Oncogenic osteomalacia

Full Text:

PDF

References


Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1-30.

Drezner MK. Tumor-induced osteomalacia. Reviews in Endocrine Metabolic Disord. 2001;2:175-86.

Jan de Beur SM. Tumor-induced osteomalacia. J Am Med Association. 2005;294:1260-7.

Saville PD, Nassim JR, Stevenson FH, Mulligan L, Carey M. Osteomalacia in Von Recklinghausen’s neurofibromatosis; metabolic study of a case. BMJ. 1955;1:1311-3.

Dent CE, Gertner JM. Hypophosphataemic osteomalacia in fibrous dysplasia. Quarterly J Med. 1976;45:411-20.

Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P et al. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. Journal of Bone and Mineral Research. 2001;16:806-13.

Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Eng J Med. 1994;330:1645-9.

Dupond JL, Mahammedi H, Prie D, Collin F, Gil H, Blagosklonov O et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone. 2005b;36:375-8.

Von Falck C, Rodt T, Rosenthal H, Langer F, Goesling T, Knapp WH et al. (68) Ga-DOTANOCPET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. Euro J Nuclear Med Molecular Imaging. 2008;35:1034.

Clunie GP, Fox PE, Stamp TC. Four cases of acquired hypophosphataemic (‘oncogenic’) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology. 2000;39:1415-21.